Renalytix AI plc is an artificial intelligence-enabled in vitro diagnostics company. The Company’s diagnostic platform, KidneyIntelX, employs artificial intelligence-enabled algorithm that combines data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record (HER) systems, to generate a patient risk score. Its patient risk score enables prediction of progressive kidney function decline in chronic kidney disease (CKD), allowing physicians and healthcare systems to manage the allocation of treatments and clinical resources to patients. KidneyIntelX provides a reportable patient risk score integrated with specific guideline-driven clinical recommendations designed to manage patient treatment and compliance outcomes. The KidneyIntelX risk score is tied to specific clinical guideline recommendations developed by the healthcare system, health insurance providers or practice groups.